Overview

Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

Status:
Recruiting

Trial end date:
2025-09-01

Target enrollment:

Participant gender:

Summary

The purposed of this research is to study the safety and clinical activity of the combination of durvalumab and a CSF-1R inhibitor (SNDX-6352) in people with Intrahepatic Cholangiocarcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators:

AstraZeneca
Syndax Pharmaceuticals

Treatments:

Antibodies
Antibodies, Monoclonal
Durvalumab